Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp200 | Diabetes: Pharmacotherapy | ECE2019

A liver selective knockdown of Dpp4 by therapeutic siRNA affects lipid metabolism but fails to improve glucose control in diabetic mice

Wolfgang Gorgens Sven , Jahn-Hofmann Kerstin , Metz-Weidmann Christiane , Schwahn Uwe , Wohlfart Paulus , Schafer Matthias , Bielohuby Maximilian

Objective: The exopeptidase dipeptidyl peptidase 4 (Dpp4) selectively cleaves N-terminal dipeptides from several substrates, including cytokines, growth factors, neuropeptides, and the incretin hormones. The systemic inhibition of Dpp4 by the so-called gliptins (oral Dpp4 inhibitors) represents an effective and established treatment option for type 2 diabetes (T2D). In the current study we investigated in healthy as well as in obese and diabetic mice if a liver selective knock...

ea0056gp110 | Diabetes Translational | ECE2018

Knock-down of class 2a histone deacetylases (HDACs) in hepatocytes of healthy mice does not affect gluconeogenesis but is associated with increased hematopoiesis

Bielohuby Maximilian , Raichur Suryaprakash , Stolte Manuela , Hemmann Ulrike , Gorgens Sven W , Wohlfart Paulus , Jahn-Hofmann Kerstin , Brunner Bodo , Tennagels Norbert

Class 2a HDACs (i.e. HDAC 4, 5, 7 and 9) are involved in the regulation of gluconeogenesis and accordingly, their inhibition has been shown to result in lower blood glucose and improved pyruvate tolerance in diabetic mice. However, pan-inhibition of HDACs is not a viable approach for chronic treatment of type 2 diabetes (T2D) due to induction of severe side effects in various tissues. We now have investigated in vitro and in vivo efficacy and safety of a live...